Skip to contentP
Protagenic Therapeutics, Inc.\new
P
PTIXProtagenic Therapeutics, Inc.\new Q1 2021 · 10-Q
Revenue$0.00$0.00no prior Q1 2020 on file Net Income-$1.21M-$1.21MN/M vs Q1 2020 EPS Diluted-$0.11-$0.11N/M vs Q1 2020 Operating Income-$1,206,190N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protagenic Therapeutics, Inc.\new · CIK 1022899 · Engraved from SEC EDGAR
ended Mar 31, 2021 · filed May 17, 2021 · 47 d after period end